188 related articles for article (PubMed ID: 21673953)
1. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol.
Huang Z; Wang H; Lu M; Sun C; Wu X; Tan Y; Ye C; Zhu G; Wang X; Cai L; Li X
PLoS One; 2011; 6(6):e20669. PubMed ID: 21673953
[TBL] [Abstract][Full Text] [Related]
2. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column.
Huang Z; Ye C; Liu Z; Wang X; Chen H; Liu Y; Tang L; Zhao H; Wang J; Feng W; Li X
Bioconjug Chem; 2012 Apr; 23(4):740-50. PubMed ID: 22433083
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting hypoglycemic effect of modified FGF-21 analog with polyethylene glycol in type 1 diabetic mice and its systematic toxicity.
Ye X; Qi J; Wu Q; Yu D; Li S; Wu Y; Li D
Eur J Pharmacol; 2016 Jun; 781():198-208. PubMed ID: 27089817
[TBL] [Abstract][Full Text] [Related]
4. One-step production of bioactive proteins through simultaneous PEGylation and refolding.
Niu J; Zhu Y; Song L; Xie Y; Zhang Y; Wang H; Li X; Liu B; Cai L; Huang Z
Bioconjug Chem; 2014 Jan; 25(1):63-71. PubMed ID: 24341776
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation.
Ye X; Qi J; Sun G; Ren G; Zhu S; Wu Y; Yu D; Zhao J; Liu M; Li D
Curr Pharm Biotechnol; 2013; 14(15):1287-98. PubMed ID: 25106652
[TBL] [Abstract][Full Text] [Related]
6. Acceleration of diabetic-wound healing with PEGylated rhaFGF in healing-impaired streptozocin diabetic rats.
Huang Z; Lu M; Zhu G; Gao H; Xie L; Zhang X; Ye C; Wang Y; Sun C; Li X
Wound Repair Regen; 2011; 19(5):633-44. PubMed ID: 22092801
[TBL] [Abstract][Full Text] [Related]
7. Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.
Ye X; Qi J; Wu Y; Yu D; Xu P; Li S; Zhu S; Wu Q; Ren G; Li D
Diabetes Metab; 2015 Feb; 41(1):82-90. PubMed ID: 25451186
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice.
Ye X; Qi J; Ren G; Xu P; Wu Y; Zhu S; Yu D; Li S; Wu Q; Muhi RL; Li D
Endocrine; 2015 Aug; 49(3):683-92. PubMed ID: 25557015
[TBL] [Abstract][Full Text] [Related]
9. A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog.
Song L; Zhu Y; Wang H; Belov AA; Niu J; Shi L; Xie Y; Ye C; Li X; Huang Z
Biomaterials; 2014 Jun; 35(19):5206-15. PubMed ID: 24685265
[TBL] [Abstract][Full Text] [Related]
10. Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice.
Zhao L; Wang H; Xie J; Chen Z; Li X; Niu J
BMC Biotechnol; 2017 Jul; 17(1):58. PubMed ID: 28676059
[TBL] [Abstract][Full Text] [Related]
11. Pilot-scale production and characterization of PEGylated human FGF-21 analog.
Ye X; Qi J; Yu D; Li S; Wu Q; Wu Y; Ren G; Han J; Li D
J Biotechnol; 2016 Jun; 228():8-17. PubMed ID: 27109774
[TBL] [Abstract][Full Text] [Related]
12. Enhanced protection of modified human acidic fibroblast growth factor with polyethylene glycol against ischemia/reperfusion-induced retinal damage in rats.
Huang Z; Zheng Q; Wu X; Su Z; Xu H; Tan Y; Feng W; Li X; Cai L
Toxicol Lett; 2007 Apr; 170(2):146-56. PubMed ID: 17416472
[TBL] [Abstract][Full Text] [Related]
13. A novel solid-phase site-specific PEGylation enhances the in vitro and in vivo biostabilty of recombinant human keratinocyte growth factor 1.
Huang Z; Zhu G; Sun C; Zhang J; Zhang Y; Zhang Y; Ye C; Wang X; Ilghari D; Li X
PLoS One; 2012; 7(5):e36423. PubMed ID: 22574160
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a combination of high and low dosage of PEGylated FGF-21 in treatment of diabetes in db/db mice.
Xu P; Zhang Y; Song L; Khoso MH; Li J; Jiang X; He J; Li J; Ma X; Ren G; Li D
Biomed Pharmacother; 2016 Dec; 84():97-105. PubMed ID: 27643551
[TBL] [Abstract][Full Text] [Related]
17. Heparin-poloxamer hydrogel-encapsulated rhFGF21 enhances wound healing in diabetic mice.
Liu H; Zhao Y; Zou Y; Huang W; Zhu L; Liu F; Wang D; Guo K; Hu J; Chen J; Ye L; Li X; Lin L
FASEB J; 2019 Sep; 33(9):9858-9870. PubMed ID: 31166803
[TBL] [Abstract][Full Text] [Related]
18. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents.
Mu J; Pinkstaff J; Li Z; Skidmore L; Li N; Myler H; Dallas-Yang Q; Putnam AM; Yao J; Bussell S; Wu M; Norman TC; Rodriguez CG; Kimmel B; Metzger JM; Manibusan A; Lee D; Zaller DM; Zhang BB; DiMarchi RD; Berger JP; Axelrod DW
Diabetes; 2012 Feb; 61(2):505-12. PubMed ID: 22210323
[TBL] [Abstract][Full Text] [Related]
19. Production of active human FGF21 using tobacco mosaic virus-based transient expression system.
Fan J; Wang Y; Huang S; Xing S; Wei Z
Growth Factors; 2021; 39(1-6):37-44. PubMed ID: 35188043
[TBL] [Abstract][Full Text] [Related]
20. Chemical modification of recombinant human keratinocyte growth factor 2 with polyethylene glycol improves biostability and reduces animal immunogenicity.
Huang Z; Ni C; Chu Y; Wang S; Yang S; Wu X; Wang X; Li X; Feng W; Lin S
J Biotechnol; 2009 Jul; 142(3-4):242-9. PubMed ID: 19477206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
